Bally's Corporation (BALY)
Bally's Corporation is a diversified gaming, sports betting, and interactive entertainment company. Founded in 2004 and headquartered in Providence, Rhode Island, it operates a portfolio of casinos, resorts, and sportsbooks across the United States. Bally's is known for its land-based casinos, as well as its expansion into online betting and gaming platforms, leveraging its brand and expertise in entertainment to cater to a broad customer base.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 20, 2020 | $0.10 | 2020-03-05 | 2020-03-06 |
| October 25, 2019 | $0.10 | 2019-10-11 | 2019-10-15 |
| July 23, 2019 | $0.10 | 2019-07-08 | 2019-07-09 |
Dividends Summary
- Bally's Corporation has issued 3 dividend payments over the past 1 years
- The most recent dividend was paid 2043 days ago, on March 20, 2020
- The highest dividend payed out to investors during this period was $0.10 per share
- The average dividend paid during this period was $0.10 per share.
Company News
Gaming and Leisure Properties (GLPI) is investing $1.19 billion to develop a 178,000 sq ft casino resort in Chicago's River West neighborhood with Bally's Corporation, featuring a 500-room hotel, extensive gaming facilities, and community amenities, with expected opening in Q4 2026.
Gaming and Leisure Properties reported mixed Q2 2025 results with record non-GAAP earnings of $0.96 per share, but experienced a significant 27.2% drop in net income due to higher credit loss provisions and a pessimistic economic forecast.
Bally's reported mixed earnings, with a surprise profit but continued revenue misses. Investors are uncertain about the company's turnaround strategy and growth prospects amid a challenging consumer environment.
While the top- and bottom-line numbers for Bally's (BALY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Kidpik Co...